Subscriptions are the base layer. The larger expansion: AimwellBio can monetize the verified biomedical intelligence workflow across APIs, expert networks, paid assessments, premium reports, and sovereign deployments. Seven primary revenue verticals, not sixteen scattered ideas.
AimwellBio does not sell public data. AimwellBio sells the structured intelligence layer that makes biomedical data usable, defensible, and decision-ready before it reaches a decision someone has to defend.
Public data tells you what exists. AimwellBio tells you what matters, what changed, what is weak, and what deserves action.
The traditional model sells the data. The category-defining model sells the workflow around the data. Seven steps. Seven revenue verticals. Each step is a place to charge a credentialed buyer who has already noticed the problem.
| Layer | Revenue Type | Primary Buyer | Why It Scales |
|---|---|---|---|
| 1. Subscription Access | Recurring | Professionals, teams, enterprises | User density and habit formation |
| 2. On-Demand Verdicts | Artifact / credits | Investors, BD teams, executives | Repeat decision artifacts at moments of high stakes |
| 3. Paid Assessments | Project revenue | Buyers with urgent risk | Immediate monetization of urgency, before procurement |
| 4. FHIN Association | Membership / network | Professionals, institutions | Human trust layer and network effects |
| 5. API & Data Licensing | Usage / license | Platforms, partners, investors | Embedded infrastructure inside other platforms |
| 6. Premium Reports / Publishing | Productized intelligence | Professionals, investors, sponsors | Authority, lead generation, and cash flow |
| 7. Sovereign / Institutional | Strategic contracts | Ministries, national institutions | Large-scale infrastructure, long-cycle revenue |
The base layer. Free education at the bottom, sovereign engagements at the top. Every tier feeds the user-density and institutional-memory effects that compound.
| Tier | Price | Buyer |
|---|---|---|
| Free · Biopharma AI Risk Brief | $0 | Cold audience, Apollo prospects, press traffic |
| Observer | Free · credentialed | Doctors, researchers, regulatory, biopharma pros, capital allocators |
| AIMN:VERDICT | from $199 / mo | Users needing on-demand entity evidence |
| Signal | $279 / mo | Individual practitioners · single therapeutic area |
| Shield | $449 / mo | Higher-exposure practitioners · multiple domains |
| Command | $749 / mo | Multi-practitioner operations and small teams |
| Growth | from $48,000 / yr | Growth-stage biotech / pharma · 50–500 employees |
| Enterprise | from $120,000 / yr | Enterprise / institutional · 500+ employees |
| Institutional | from $180,000 / yr | Research institutions and academic centers |
| Sovereign | by arrangement | National systems and sovereign mandates |
| Tier | Moat mechanism |
|---|---|
| Free / Brief | Audience capture and trust formation |
| Observer | Credentialed professional graph |
| Verdict | Repeat decision artifacts and cited outputs |
| Signal | Watchlist habit and weekly intelligence loop |
| Shield | Source-risk history and professional dependency |
| Command | Team workflow and multi-user memory |
| Growth / Enterprise / Institutional | Deployment depth, audit trails, peer-review workflow |
| Sovereign | Jurisdictional mapping and national deployment architecture |
Closer to artifact-purchasing than monitoring. The buyer pays for a cited 2 to 3 page verdict on a specific entity, asset, or evidence set. Recurring spend without a calendar commitment.
| Product | Price model | Buyer |
|---|---|---|
| Verdict Starter | $199/mo | Individual professionals · limited monthly verdicts |
| Extra Verdict Credits | $25–$99 each | Pros / investors needing one more entity check |
| Company / Asset Verdict | $500–$2,500 | Investors, BD teams |
| Disease-Area Verdict Pack | $2,500–$10,000 | Medical affairs, investors |
| Investor Diligence Verdict | $5,000–$25,000 | Funds, family offices |
Anyone can summarize a company. The moat is: cited evidence chain, confidence label, adversarial review logic, "what changed" context, entity history, comparable entities, prior verdict memory, escalation logic, exportable professional format. A verdict is not a report. It is a decision artifact.
This is how Apollo, press, LinkedIn, and investor interest becomes money without waiting for full procurement. A single exposed brief, trial update, regulatory concern, or investment question becomes a paid engagement.
| Assessment | Price range | Buyer |
|---|---|---|
| Shield Source-Risk Audit | $500–$2,500 | Regulatory, compliance, biotech teams |
| Signal Review | $1,500–$5,000 | Medical affairs, clinical development |
| Verdict Decision Assessment | $2,500–$10,000 | Executives, investors, BD teams |
| Investor Diligence Assessment | $5,000–$25,000 | VCs, funds, family offices |
| Enterprise Intelligence Assessment | $15,000–$50,000 | Biotech, pharma, CRO, health system, institution |
A client could technically search public data themselves. But they usually cannot quickly produce: claim extraction, source-chain evaluation, currentness review, cross-source contradiction detection, regulatory context, decision-framed summary, confidence labels, professionally formatted memo, and a repeatable workflow. The product is not information. It is judgment structure.
And every assessment is a learning event. We see what buyers worry about, which claims fail, which sources matter, what signals trigger escalation, which workflows convert. The assessments train the product roadmap.
Not just a community. Not just contributors. A credentialed professional network for the people healthcare already trusts — physicians, researchers, clinicians, regulatory professionals, investors, and institutional leaders.
The model sits between ALSD-style professional association, ResearchGate-style identity, and GLG-style expert network, with stronger publishing and signal context layered in.
| Layer | Price | Deliverable |
|---|---|---|
| Public Professional Profile | Free | Profile, publications, expertise tags, linkable identity, network gravity |
| FHIN Professional Plus | $999 / yr · proposed | Enhanced profile, featured work, expert-availability marketplace, job board, networking |
| FHIN Institutional Member | $10,000–$50,000 / yr · proposed | Institution page, group profiles, research announcements, expert network visibility |
| FHIN Council / Fellows | Invite-only | Status, expert panels, advisory review, featured thought leadership |
| Product | Price range |
|---|---|
| Expert Review Marketplace · enterprise-paid | $500–$5,000 per review |
| Job Post · standard | $299 |
| Job Post · featured | $799 |
| Institution Recruiting Package | $2,500–$10,000 |
| Sponsored Talent Campaign | $10,000+ |
ResearchGate gives researchers visibility around their work. FHIN goes further: visibility plus applied intelligence contributions, plus signal relevance, plus the network of doctors and regulatory and investors who shape the field. Paper-centric identity → expertise, review, signal, press, and professional influence identity.
API licensing is how AimwellBio becomes infrastructure inside other platforms. Selected partners access the structured intelligence layer through approved endpoints. The subscription user sees the interface. The API customer licenses the intelligence layer underneath.
| API Layer | What it provides |
|---|---|
| Signal API | Structured updates by company, drug, indication, disease area, regulatory body, trial, publication, market event |
| Shield API | Source-chain checks, weak citation flags, stale evidence flags, unsupported claim indicators |
| Verdict API | Decision-support outputs for approved entities, assets, evidence sets |
| Atlas API | Disease-area, geography, entity, burden, movement, regulatory heat-map intelligence |
| Watchlist API | Monitored entity updates and alert feeds |
| Document Intelligence API | Claim extraction, source-risk review, evidence traceability on uploaded documents |
| FHIN Context API | Permissioned expert-context tags and domain expertise signals (no private professional data) |
| Tier | Price | Buyer |
|---|---|---|
| Developer Sandbox | Invite-only | Strategic prospects · sample endpoints, no production rights |
| Startup API | from $2,500 / mo | Early platforms and small research tools · capped calls |
| Professional API | from $7,500 / mo | Investors, research groups, serious platforms · Signal + Shield endpoints |
| Enterprise API | from $25,000 / mo | Pharma, CROs, health systems, data platforms · custom endpoints, SLA, security review |
| Strategic License | Request access | Large platforms, sovereign / institutional partners · scoped per engagement |
Each report is both a product and a proof artifact. Reports drive search visibility, press momentum, lead generation, enterprise conversation starters, and investor credibility — while generating revenue on their own.
| Product | Price | Buyer |
|---|---|---|
| Biopharma AI Risk Brief | Free | Cold audience · lead magnet |
| Disease-Area Signal Report | $299–$999 | Professionals, researchers, investors |
| Company / Asset Intelligence Report | $1,500–$5,000 | Investors, BD teams, biotech operators |
| Regulatory Risk Snapshot | $2,500–$7,500 | Regulatory teams, investors |
| Investor Portfolio Brief | $5,000–$25,000 | Funds, family offices |
| Sponsored Intelligence Report | $10,000–$50,000 | Institutions, sponsors, associations · clearly labeled editorial-review |
Curated source chain, what changed, why now, who is exposed, source confidence, decision implications, Atlas visuals, Signal layer, Shield review, FHIN expert context where available, exportable executive format. Not recycled open-source summaries.
Not sold as software. Sold as infrastructure. Buyers include national health ministries, sovereign wealth funds, public health agencies, national research bodies, university networks, large hospital systems, biotech industrial strategy programs, and international regulatory bodies.
| Product | Price range | Buyer |
|---|---|---|
| Sovereign Discovery Assessment | $50,000–$150,000 | Ministries, institutions, strategic buyers |
| National Disease-Area Intelligence Room | $250,000–$1M / yr | Public health, ministry, national program |
| Ministry / Public Health Layer | $500,000–$2.5M / yr | Health ministries, public agencies |
| Sovereign Research Network + FHIN Deployment | $750,000–$3M / yr | National research bodies, universities |
| Full Strategic Deployment | $2M+ / yr | Sovereign / national-scale deployment |
Jurisdiction-specific configuration. Localized regulatory mapping. Private deployment. Data governance. Expert network. Institutional relationships. Custom workflows. Long-cycle contracts. National research integration. These cannot be retroactively assembled by a competitor starting today.
Anyone can pull from FDA.gov, PubMed, ClinicalTrials.gov, SEC, or SEER. The moat is what happens after.
| Input | AimwellBio layer | Output |
|---|---|---|
| FDA updates | Source-chain review | Risk-labeled intelligence |
| Clinical trial updates | Signal classification | Decision-relevant alerts |
| Publications | Confidence labeling | Cited briefs |
| Company movement | Entity mapping | Watchlist updates |
| Expert context | FHIN overlay | Professional interpretation |
| User behavior | Institutional memory | Better future prioritization |
| Open-source pull | AimwellBio output |
|---|---|
| A list of FDA updates | A ranked signal briefing with relevance and risk |
| A PubMed search | A source-backed evidence review |
| A ClinicalTrials.gov record | A trial movement signal with implications |
| A SEER table | A disease-area context layer connected to current activity |
| A general-purpose AI summary | A confidence-labeled output with source traceability |
| A spreadsheet | A workflow that remembers, updates, and escalates |
The next standard in healthcare intelligence will not be more data. It will be verified intelligence.
It may feel like teams already have enough dashboards. The harder question is whether they can defend the intelligence behind the next decision.
Old intelligence was retrospective. AI made it faster. Verification became the missing layer. AimwellBio educates the market before it sells.
The value is not the software. The value is fewer blind spots, faster clarity, and decision artifacts that can be defended.
Every revenue path begins with education — the Biopharma AI Risk Brief — then moves into a concrete offer: audit, assessment, verdict, report, membership, API, or deployment.
AimwellBio is not limited to monthly subscriptions. Subscription access is the base layer. The expansion story is larger: a verified biomedical intelligence infrastructure platform that monetizes access, APIs, expert networks, assessments, reports, and sovereign deployments.
The company's long-term value is not in collecting public data. It is in transforming fragmented healthcare intelligence into trusted workflows that professionals, institutions, platforms, and governments can use before decisions are made.
The healthcare organizations that continue relying on static reports, disconnected databases, and unsupported AI summaries will not lose because they lacked information. They will lose because they could not verify, prioritize, and act on it fast enough.
Read the Biopharma AI Risk Brief first. It is what AimwellBio hands every team — investors included — before any commercial conversation. The Brief is open to credentialed professionals. The conversation that follows is by appointment.
Read the Brief → Investor Briefing Request →